Risk factors for mortality among patients with Pseudomonas aeruginosa bacteremia - retrospective multicenter study.
To evaluate risk factors for 30-day mortality among hospitalized patients with Pseudomonas aeruginosa bacteremia, a highly fatal condition. Retrospective study conducted in 25 centers, 9 countries, including 2396 patients between January 1, 2009, through October 31, 2015. Univariable and multivariable analyses of risk factors were conducted for the entire cohort and for patients surviving >= 48 hours. Propensity score for predictors of appropriate empirical therapy was introduced into the analysis. Of 2396 patients included, 636 patients died within 30 days (26.5%). Significant predictors of mortality in multivariable analysis included patient related factors: age (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.01-1.03), female gender (OR 1.34, 95% CI 1.03-1.77), functional capacity: bedridden (1.99, 1.24-3.21), recent hospitalization (1.43, 1.07-1.92), concomitant corticosteroids (1.33, 1.02-1.73), and Charlson comorbidity score (1.05, 1.01-1.93). Infection related factors were: multidrug resistant Pseudomonas (1.52, 1.15-2.1), non-urinary source (2.44, 1.54-3.85), and Sequential Organ Failure Assessment (SOFA) score (1.27, 1.18-1.36). Inappropriate empirical therapy was not associated with increased mortality (0.81, 0.49-1.33). Among 2135 patients surviving 48 hours, hospital acquired infection (1.59, 1.21-2.09), baseline endotracheal tube (1.63, 1.13-2.36), and intensive care unit admission (1.53, 1.02-2.28) were additional risk factors. Risk factors for mortality among patients with P. aeruginosa were mostly irreversible. Early appropriate empirical therapy was not associated with reduced mortality. Further research should be conducted to explore sub-groups that may not benefit from broad spectrum antipseudomonal empirical therapy. Efforts should focus on prevention of infection, mainly hospital acquired infection and multidrug resistant pseudomonal infection.